MORPHIC Trademark

Trademark Overview

On Wednesday, June 23, 2021, a trademark application was filed for MORPHIC with the United States Patent and Trademark Office. The USPTO has given the MORPHIC trademark a serial number of 90790093. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Tuesday, August 27, 2024. This trademark is owned by Morphic Therapeutic, Inc.. The MORPHIC trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals and pharmaceutical preparations for use in the treatment of autoimmune, cardiovascular and metabolic diseases, as well as fibrosis and cancer
morphic

General Information

Serial Number90790093
Word MarkMORPHIC
Filing DateWednesday, June 23, 2021
Status732 - THIRD EXTENSION - GRANTED
Status DateTuesday, August 27, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 3, 2023

Trademark Statements

Goods and ServicesPharmaceuticals and pharmaceutical preparations for use in the treatment of autoimmune, cardiovascular and metabolic diseases, as well as fibrosis and cancer

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, September 8, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameMorphic Therapeutic, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWaltham, MA 02451
Party NameMorphic Therapeutic, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWaltham, MA 02451

Trademark Events

Event DateEvent Description
Saturday, June 26, 2021NEW APPLICATION ENTERED
Wednesday, September 8, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, March 15, 2022ASSIGNED TO EXAMINER
Tuesday, March 15, 2022NON-FINAL ACTION WRITTEN
Tuesday, March 15, 2022NON-FINAL ACTION E-MAILED
Tuesday, March 15, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, September 15, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, September 15, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, September 16, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, November 30, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 14, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 3, 2023PUBLISHED FOR OPPOSITION
Tuesday, January 3, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 28, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, August 21, 2023SOU TEAS EXTENSION RECEIVED
Monday, August 21, 2023SOU EXTENSION 1 FILED
Monday, August 21, 2023SOU EXTENSION 1 GRANTED
Wednesday, August 23, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 28, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, February 28, 2024SOU EXTENSION 2 GRANTED
Wednesday, February 28, 2024SOU EXTENSION 2 FILED
Thursday, February 29, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 30, 2024TEAS STATEMENT OF USE RECEIVED
Tuesday, August 27, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, August 27, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 27, 2024SOU EXTENSION 3 GRANTED
Tuesday, August 27, 2024SOU EXTENSION 3 FILED
Wednesday, August 28, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, August 28, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, August 28, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, August 28, 2024TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS

Related Keywords

morphic diseases well fibrosis cancer metabolic cardiovascular pharmaceutical preparations treatment autoimmune